Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 168

1.

The preclinical natural history of serous ovarian cancer: defining the target for early detection.

Brown PO, Palmer C.

PLoS Med. 2009 Jul;6(7):e1000114. doi: 10.1371/journal.pmed.1000114. Epub 2009 Jul 28.

PMID:
19636370
[PubMed - indexed for MEDLINE]
Free PMC Article
2.
3.

Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.

Casey MJ, Bewtra C.

Fam Cancer. 2004;3(3-4):265-81. Review.

PMID:
15516851
[PubMed - indexed for MEDLINE]
4.

The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer.

Fishman DA, Cohen L, Blank SV, Shulman L, Singh D, Bozorgi K, Tamura R, Timor-Tritsch I, Schwartz PE.

Am J Obstet Gynecol. 2005 Apr;192(4):1214-21; discussion 1221-2.

PMID:
15846205
[PubMed - indexed for MEDLINE]
5.

Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.

Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD, Kim-Sing C, Wagner T, Tung N, Couch F, Stoppa-Lyonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel J, Sun P, Narod SA; Hereditary Ovarian Cancer Clinical Study Group.

JAMA. 2006 Jul 12;296(2):185-92.

PMID:
16835424
[PubMed - indexed for MEDLINE]
6.

Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.

Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT.

Gynecol Oncol. 2005 May;97(2):457-67.

PMID:
15863145
[PubMed - indexed for MEDLINE]
7.

Prevention and early detection of ovarian cancer: mission impossible?

Bast RC Jr, Brewer M, Zou C, Hernandez MA, Daley M, Ozols R, Lu K, Lu Z, Badgwell D, Mills GB, Skates S, Zhang Z, Chan D, Lokshin A, Yu Y.

Recent Results Cancer Res. 2007;174:91-100. Review.

PMID:
17302189
[PubMed - indexed for MEDLINE]
8.

Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.

Crum CP, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y.

Clin Med Res. 2007 Mar;5(1):35-44. Review.

PMID:
17456833
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.

Rabban JT, Barnes M, Chen LM, Powell CB, Crawford B, Zaloudek CJ.

Am J Surg Pathol. 2009 Aug;33(8):1125-36. doi: 10.1097/PAS.0b013e31819e986a.

PMID:
19440148
[PubMed - indexed for MEDLINE]
10.

Pathologic findings in prophylactic oophorectomy specimens in high-risk women.

Leeper K, Garcia R, Swisher E, Goff B, Greer B, Paley P.

Gynecol Oncol. 2002 Oct;87(1):52-6.

PMID:
12468342
[PubMed - indexed for MEDLINE]
11.

Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature.

Carcangiu ML, Peissel B, Pasini B, Spatti G, Radice P, Manoukian S.

Am J Surg Pathol. 2006 Oct;30(10):1222-30.

PMID:
17001151
[PubMed - indexed for MEDLINE]
12.

Breast cancer and ovarian cancer genetics.

Edlich RF, Winters KL, Lin KY.

J Long Term Eff Med Implants. 2005;15(5):533-45. Review.

PMID:
16218901
[PubMed - indexed for MEDLINE]
13.

Biology of epithelial ovarian cancer: implications for screening women at high genetic risk.

Hogg R, Friedlander M.

J Clin Oncol. 2004 Apr 1;22(7):1315-27.

PMID:
15051780
[PubMed - indexed for MEDLINE]
14.

Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.

Manchanda R, Abdelraheim A, Johnson M, Rosenthal AN, Benjamin E, Brunell C, Burnell M, Side L, Gessler S, Saridogan E, Oram D, Jacobs I, Menon U.

BJOG. 2011 Jun;118(7):814-24. doi: 10.1111/j.1471-0528.2011.02920.x. Epub 2011 Mar 10.

PMID:
21392246
[PubMed - indexed for MEDLINE]
15.

Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?

van der Velde NM, Mourits MJ, Arts HJ, de Vries J, Leegte BK, Dijkhuis G, Oosterwijk JC, de Bock GH.

Int J Cancer. 2009 Feb 15;124(4):919-23. doi: 10.1002/ijc.24038.

PMID:
19035463
[PubMed - indexed for MEDLINE]
16.

Systematic evaluation of candidate blood markers for detecting ovarian cancer.

Palmer C, Duan X, Hawley S, Scholler N, Thorpe JD, Sahota RA, Wong MQ, Wray A, Bergan LA, Drescher CW, McIntosh MW, Brown PO, Nelson BH, Urban N.

PLoS One. 2008 Jul 9;3(7):e2633. doi: 10.1371/journal.pone.0002633.

PMID:
18612378
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.

Reitsma W, de Bock GH, Oosterwijk JC, Bart J, Hollema H, Mourits MJ.

Eur J Cancer. 2013 Jan;49(1):132-41. doi: 10.1016/j.ejca.2012.07.021. Epub 2012 Aug 21.

PMID:
22921157
[PubMed - indexed for MEDLINE]
18.

Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.

Domchek SM, Friebel TM, Garber JE, Isaacs C, Matloff E, Eeles R, Evans DG, Rubinstein W, Singer CF, Rubin S, Lynch HT, Daly MB, Weitzel J, Ganz PA, Pichert G, Olopade OI, Tomlinson G, Tung N, Blum JL, Couch F, Rebbeck TR.

Breast Cancer Res Treat. 2010 Nov;124(1):195-203. doi: 10.1007/s10549-010-0799-x. Epub 2010 Feb 24.

PMID:
20180014
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.

Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL, Saigo PE, Almadrones LA, Barakat RR, Brown CL, Chi DS, Curtin JP, Poynor EA, Hoskins WJ.

JAMA. 2000 May 3;283(17):2260-5.

PMID:
10807385
[PubMed - indexed for MEDLINE]
20.

Borderline ovarian tumours: retrospective analysis of twenty-one cases.

Saygili U, Uslu T, Erten O, Do─čan E.

Eur J Gynaecol Oncol. 1998;19(2):182-5.

PMID:
9611063
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk